Iantrek Raises $42M for Glaucoma Therapy

Iantrek has announced the successful completion of a $42 million Series C financing round. The funding will support the U.S. commercial launch of AlloFlo Uveo, a novel surgical solution targeting the uveoscleral outflow pathway, as well as the continued development of the company’s broader pipeline of bio-interventional and microinterventional technologies.

Series C Financing to Support Glaucoma Therapy Development

The Series C round was led by U.S. Venture Partners (USVP) and included participation from aMoon Fund, along with existing investors Visionary Ventures, Sectoral Asset Management, Radius Special Situations Fund, and Civilization Ventures.

“Our mission is to address a major unmet need in glaucoma care, and this fundraise marks a pivotal moment in helping us achieve it,” said Adam Szaronos, CEO of Iantrek. “More than 2.5 million eyes in the United States are experiencing waning efficacy from previous MIGS procedures targeting the trabecular pathway. AlloFlo Uveo enables access to the uveoscleral pathway, the eye’s other natural drainage system—much like giving a thoracic surgeon the ability to enhance the second lung.”

Casey Tansey, General Partner at USVP, added: “This raise reflects strong confidence in Iantrek’s bold vision and disruptive approach to interventional glaucoma. Their platform is redefining what’s possible by combining simplicity, precision, and improved outcomes.”

Clinical Evidence Supporting Efficacy and Safety

In 2025, the American Academy of Ophthalmology published a peer-reviewed study in Ophthalmology Science evaluating bio-reinforced cyclodialysis using AlloFlo Uveo. The two-year data demonstrated a 34% mean reduction in intraocular pressure (IOP), a >60% decrease in IOP-lowering medication use, and no serious product-related adverse events.

“With approximately 3,000 procedures performed through its early access program, surgeon demand for uveoscleral pathway access is clear,” said Sean Ianchulev, MD, MPH, professor of ophthalmology at the New York Eye and Ear of Mount Sinai and Chairman of the Board at Iantrek. “Iantrek’s bio-interventional approach is currently the only surgical solution targeting this major outflow pathway with the highest therapeutic index in glaucoma treatment.”

Expanding Pipeline and Future Outlook

Iantrek’s growing portfolio includes AlloFlo Uveo, AlloSert Uveo, and C.Rex, representing a new class of bio-interventional and microinterventional solutions designed to enhance surgical precision and restore natural aqueous outflow. AlloFlo Uveo stands out as the first allogeneic graft designed for durable implantation and bio-integration in ophthalmic applications.

The company has also completed first-in-human trials for its next-generation product, with a commercial launch anticipated in 2026.